Axsome Therapeutics (AXSM) Change in Account Payables (2015 - 2026)

Axsome Therapeutics has disclosed Change in Account Payables across 12 years of filings, most recently posting $41.2 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $41.2 million, up 201.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.0 million (down 33.97% YoY), and the FY2025 annual result was -$6.5 million, down 120.63% from the prior year.
• Change in Account Payables came in at $41.2 million for Q1 2026 at Axsome Therapeutics, up from $11.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $41.2 million in Q1 2026 to a low of -$37.4 million in Q3 2025.
• The 5-year median for Change in Account Payables is $7.2 million (2023), against an average of $5.5 million.
• Across the five-year window, Change in Account Payables surged 11172.43% in 2022 and plunged 1383.93% in 2025, its largest moves.
• Axsome Therapeutics' Change in Account Payables stood at $25.8 million in 2022, then plunged by 55.04% to $11.6 million in 2023, then plunged by 33.13% to $7.7 million in 2024, then soared by 46.05% to $11.3 million in 2025, then jumped by 263.97% to $41.2 million in 2026.
• The last three Change in Account Payables figures came in at $41.2 million (Q1 2026), $11.3 million (Q4 2025), and -$37.4 million (Q3 2025), per Business Quant data.